Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
AbbVie
(NY:
ABBV
)
188.86
+0.29 (+0.15%)
Official Closing Price
Updated: 7:00 PM EDT, Oct 18, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about AbbVie
< Previous
1
2
...
27
28
29
30
31
32
33
34
35
...
68
69
Next >
Market Rally Wobbles Amid Big Earnings Moves From Microsoft, Meta, Crocs, Cloudflare: Weekly Review
April 28, 2023
Microsoft, Meta, Cloudflare and Crocs were among the many big movers.
Via
Investor's Business Daily
How AI Is Revolutionizing Tech, and Why You Should Invest in These Leading Companies
April 28, 2023
Check out these compelling opportunities.
Via
The Motley Fool
Could Government Drug-Price Negotiations Sound The Death Knell For Biotech Stocks?
April 28, 2023
Experts fear a change in how Medicare buys drugs could slam biotech and pharma companies.
Via
Investor's Business Daily
Why AbbVie Stock Is Crashing Today
April 27, 2023
AbbVie's 2023 Q1 report isn't sitting well with shareholders today.
Via
The Motley Fool
$100 Invested In This Stock 10 Years Ago Would Be Worth $300 Today
April 27, 2023
Via
Benzinga
Why AbbVie Shares Are Trading Lower Today
April 27, 2023
AbbVie Inc (NYSE: ABBV) has reported Q1 adjusted EPS of $2.46
Via
Benzinga
Dow, Nasdaq Hold Triple-Digit Gains
April 27, 2023
The Dow Jones Industrial Average and Nasdaq Composite are both up triple-digits, despite this morning's GDP data which showed less economic growth than expected.
Via
Talk Markets
Why NETGEAR Shares Are Trading Lower By 18%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
April 27, 2023
Gainers Evelo Biosciences, Inc. (NASDAQ: EVLO) jumped 147.9% to $0.2479. Evelo Biosciences shares dropped 33% on Wednesday after the company announced top-line data from the fourth cohort of its...
Via
Benzinga
AbbVie Stock Crumbles As Humira Biosimilars Take A 25% Cut
April 27, 2023
The Humira downfall wasn't as steep an analysts expected, but AbbVie stock tumbled early Thursday.
Via
Investor's Business Daily
This Is What Whales Are Betting On AbbVie
April 25, 2023
Via
Benzinga
AbbVie Inc. (NYSE: ABBV) Making Surprising Moves in Monday Session
April 24, 2023
Via
Investor Brand Network
Price Over Earnings Overview: AbbVie
April 21, 2023
Via
Benzinga
1 Dividend Stock to Buy Hand Over Fist in May and 1 to Avoid
April 27, 2023
There's more to picking worthy dividend stocks than the forward yield.
Via
The Motley Fool
US Stocks Eye Higher Open As Meta Q1 Uplifts Tech Sector: Analyst Says 'No Earnings Recession In Cards Yet'
April 27, 2023
Tech earnings could come to the market’s rescue on Thursday, with all major index futures currently trading higher.
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
April 26, 2023
Via
Benzinga
3 Stocks You Can Keep Forever
April 16, 2023
Three solid profitable companies that are growing their businesses and their dividends.
Via
The Motley Fool
3 Reasons Why I Regret Selling AbbVie
April 16, 2023
Having the knowledge to stay steady in your convictions can be a game changer.
Via
The Motley Fool
Hagens Berman: Class Action Accuses AbbVie Inc. of Unfair Pricing of Autoimmune Drug Humira Following 470% Cost Increase
April 26, 2023
From
Hagens Berman Sobol Shapiro LLP
Via
Business Wire
A Rotation Into Defensive Stocks? Market Strength Seen In Consumer Defensive And Healthcare On Tuesday
April 25, 2023
The U.S. stock market is seeing some modest selling on Tuesday morning after a series of largely uneventful sessions last week. Two hours into the trading day, the S&P 500 was down around 0.75% and the...
Via
Benzinga
This Supercharged Dividend King Stock Might Soon Run Out of Steam
April 25, 2023
Emerging competitive threats in immunology, oncology, and medical aesthetics, along with a highly leveraged balance sheet, might dampen the drugmaker's growth trajectory post-2025.
Via
The Motley Fool
3 Winning Stocks to Buy No Matter What the Market Is Doing
April 25, 2023
The long-term picture for these stocks remains bright.
Via
The Motley Fool
The Best Stocks to Invest $20,000 in Right Now
April 23, 2023
You'll want to hold on to these top stocks for the long term.
Via
The Motley Fool
Looking Into The JEPI ETF Hype: What Is This ETF?
April 22, 2023
There's an ETF that has been the talk of the town lately. I'm not talking about Charles Schwab’s SCHD. This is about the premium income ETF JEPI from JPMorgan Chase. This high yielding ETF has garnered...
Via
Talk Markets
3 Top Dividend Kings to Buy for the Long Haul
April 22, 2023
These healthcare stocks all have above-average dividends.
Via
The Motley Fool
AbbVie's Preventive Treatment For Migraine Meets Primary Goal In Patients With Failed Medications
April 21, 2023
AbbVie Inc (NYSE: ABBV) announced data from its Phase 3 ELEVATE study, evaluating atogepant for the preventive treatment of episodic migraine in people who had previously failed two to four classes of...
Via
Benzinga
Citigroup, Dell And 2 Other Stocks Insiders Are Selling
April 20, 2023
The S&P 500 closed almost flat on Wednesday. Investors, meanwhile, focused on some notable insider trades.
Via
Benzinga
Is Merck Stock a Screaming Buy After This $11 Billion Acquisition?
April 19, 2023
Merck's move into immunology is a risky proposition.
Via
The Motley Fool
3 Dividend Stocks to Buy for a Recession-Proof Portfolio
April 15, 2023
Many investors believe we’re at the point of no return, leading us to look at some of the best dividend stocks for a recession.
Via
InvestorPlace
3 Dividend Stocks to Buy and Hold for the Next Decade
April 15, 2023
Long-term investors looking for income should especially like these stocks.
Via
The Motley Fool
FDA Strikes Down Eli Lilly's Application Seeking Approval For Ulcerative Colitis Drug
April 14, 2023
Via
Benzinga
< Previous
1
2
...
27
28
29
30
31
32
33
34
35
...
68
69
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.